EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biocure Technology's Enterprise Value is C$1.49 Mil.
Biocure Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.03 Mil. Therefore, Biocure Technology's EV-to-FCF for today is 51.38.
The historical rank and industry rank for Biocure Technology's EV-to-FCF or its related term are showing as below:
XCNQ:CURE'
s EV-to-FCF Range Over the Past 10 Years
Min: -24.86 Med: -5.28 Max: 51.38
Current: 51.38
During the past 13 years, the highest EV-to-FCF of Biocure Technology was 51.38. The lowest was -24.86. And the median was -5.28.
XCNQ:CURE's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.31
vs XCNQ:CURE: 51.38
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Biocure Technology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biocure Technology's EV-to-FCF
For the Biotechnology subindustry, Biocure Technology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocure Technology's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biocure Technology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biocure Technology's EV-to-FCF falls into.
Biocure Technology's current Enterprise Value is C$1.49 Mil.
Biocure Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Biocure Technology's PE Ratio for today is calculated as:
Biocure Technology's share price for today is C$0.015.
Biocure Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biocure Technology EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Biocure Technology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocure Technology (XCNQ:CURE) Business Description
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is in the process of preclinical trials of five majorly biosimilar products in South Korea, including Interferon Beta 1b, PEGFilgrastim, and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:CURE has been successfully added to your 